What is Standigm?
Founded in 2015 and headquartered in Seoul, South Korea, Standigm operates at the intersection of deep learning and medicinal chemistry. The company has developed a comprehensive, full-stack AI platform designed to industrialize the drug discovery process. Its core technological ecosystem includes Standigm ASK for target identification, Standigm BEST for lead selection, and Standigm Insight for drug repurposing. Furthermore, the firm has pioneered the DarkMolFactory, an automated molecular design workflow that significantly reduces the time and resource intensity typically associated with early-stage pharmaceutical research. With over 20 preclinical pipelines currently in development, Standigm is effectively transforming how therapeutic candidates are identified and validated across diverse medical domains.
How much funding has Standigm raised?
Standigm has raised a total of $56M across 2 funding rounds:
Angel/Seed
$11.5M
Other Financing Round
$44.5M
Angel/Seed (2019): $11.5M, investors not publicly disclosed
Other Financing Round (2021): $44.5M led by SKS PE, Asset One, KDB Bank, InterVest, and Daishin Private Equity
Key Investors in Standigm
KDB Bank
A major financial institution providing strategic capital to support industrial innovation and technological advancement in key sectors.
SKS PE
A private equity firm focused on growth-stage investments and supporting the scaling of high-potential technology enterprises.
InterVest
A venture capital firm specializing in identifying and nurturing innovative startups within the healthcare and biotechnology industries.
What's next for Standigm?
With the infusion of capital from its latest financing round, Standigm is well-positioned to scale its automated discovery platforms and expand its preclinical pipeline portfolio. The strategic focus will likely shift toward enhancing the integration of its AI platforms into broader industrial workflows, potentially seeking international partnerships to validate its molecular design capabilities on a global scale. As the company matures, the emphasis will remain on optimizing the efficiency of its proprietary AI engines to shorten the development lifecycle of novel therapeutics, thereby solidifying its competitive advantage in the high-stakes arena of AI-enabled drug discovery.
See full Standigm company page
